Discontinuing Strattera (Atomoxetine)
Strattera can be stopped abruptly without tapering—no gradual dose reduction is required. 1
Key Evidence from FDA Label
The FDA-approved prescribing information explicitly states: "STRATTERA can be discontinued without being tapered." 1 This is fundamentally different from many other psychiatric medications and represents the most authoritative guidance available.
Supporting Clinical Trial Data
Research confirms this approach is safe and well-tolerated:
- No discontinuation syndrome develops when atomoxetine is stopped abruptly 2
- No symptom rebound occurs beyond the expected return of underlying ADHD symptoms 2, 3
- Discontinuation-emergent adverse events are rare and occur at rates no different from placebo 2
- Blood pressure and heart rate elevations that occurred during treatment return to baseline upon stopping 4
What to Expect After Stopping
ADHD Symptom Return
- ADHD symptoms will gradually worsen after discontinuation but do not rebound below pre-treatment baseline 2
- For hyperactivity symptoms: expect return within hours to days 5
- For inattentive symptoms: may take longer to become apparent, requiring extended monitoring 5
Monitoring Timeline
Establish a monitoring plan for several weeks to months after discontinuation, as the full return of inattentive symptoms may be delayed 5. This is particularly important for patients with predominantly inattentive-type ADHD.
Adverse Event Resolution
If stopping due to side effects, common adverse events resolve with median times of 3-53 days after discontinuation 4:
- Gastrointestinal symptoms (nausea, decreased appetite): resolve relatively quickly
- Male sexual dysfunction: may persist longer (up to 53 days median) 4
Clinical Decision Framework
Before discontinuing, obtain:
- History of previous ADHD symptoms and their severity
- Documentation of medication response
- Collateral information from family/teachers if available 5
This prevents "needless and unexpected return of symptoms" and ensures the decision to stop is appropriate 5.
Reasons to discontinue include:
- Completed appropriate treatment duration with symptom resolution
- Intolerable adverse effects
- Lack of efficacy
- Patient/family preference
- Medication no longer clinically indicated 5
Important Caveats
While atomoxetine itself requires no taper, if the patient is on multiple psychiatric medications, follow general psychotropic discontinuation principles 5:
- Remove adjunctive/augmenting agents first
- Keep medications with better long-term safety profiles
- Maintain medications managing side effects until after the primary agent is fully discontinued
Do not confuse atomoxetine with other psychiatric medications (SSRIs, SNRIs, benzodiazepines) that DO require gradual tapering to avoid withdrawal syndromes 5. The evidence for atomoxetine is uniquely permissive of abrupt discontinuation.